Core Insights - Radiopharm Theranostics has initiated its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 for advanced prostate cancer [1][3] - The trial aims to evaluate the safety, tolerability, and preliminary clinical activity of RAD 402, with a focus on determining the Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) [2] Group 1: Product Development - RAD 402 is designed to selectively target KLK3-expressing tumors while minimizing off-target exposure, demonstrating strong tumor uptake and minimal bone or marrow involvement in preclinical studies [3][4] - The preclinical proof-of-concept studies showed a hepatic excretion profile consistent with expectations for a monoclonal antibody, indicating a favorable biodistribution [4] Group 2: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors, including lung, breast, prostate, and brain metastases [5]